Vincent Anzalone | Vice President, Investor Relations |
Christopher Anzalone | President and Chief Executive Officer |
Javier San Martin | Chief Medical Officer |
James Hamilton | Chief, Discovery and Translational Medicine |
Ken Myszkowski | Chief Financial Officer |
Tracy Oliver | Chief Commercial Officer |
Patrick O’Brien | Chief Operating Officer and General Counsel |
Ellie Merle | UBS |
Maury Raycroft | Jefferies |
Mayank Mamtani | B. Riley |
Joel Beatty | Baird |
Madhu Kumar | Goldman Sachs |
Luca Issi | RBC Capital Markets |
Prakhar Agarwal | Cantor |
Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. [Operator Instructions] I will now hand the conference over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.
Thanks so much. Good afternoon and thank you for joining us today to discuss Arrowhead’s results for its fiscal 2023 first quarter ended December 31, 2022.